The worldwide antithrombin market is expected to expand due to the rising prevalence of diseases such as sepsis, congenital antithrombin deficiency, disseminated intravascular coagulation (DIC)

According to the deep-dive market assessment study conducted by Growth+ Reports, the antithrombin market was pegged at ~US$ 550 million in 2021. The market is expected to witness a CAGR of ~ 3.90% from 2022 to 2030.

Antithrombins deactivate several enzymes of coagulation system to prevent excessive blood clots. Growing use of antithrombin in conjunction with heparin due to the increased reporting of diseases like sepsis, intravascular coagulations, and myocardial infractions, high incidences of coagulation disorders, increased rates of kidney and heart failure (used extensively in dialysis and open-heart surgeries) are the key drivers of the global antithrombin market. However, because of animal testing restrictions, there is limited research on pipeline drugs being performed is a prominent challenge to the global market. Also, issues including the rising usage of biologics and the high price of antithrombin drugs are limiting the global antithrombin market.

Diseases such as sepsis and myocardial infractions are increasing significantly. According to CDC (Centers for Disease Control and Prevention), in 2019, 17.9 million deaths worldwide were attributable to CVDs (Cardiovascular Disorders), or 32% of all fatalities were noted. 85 percent of these fatalities were attributable to heart attacks and strokes. In these circumstances, antithrombins or blood thinners are advised to prevent blood clots, which eventually reduces the risk of heart attack and stroke. Antithrombins acts by preventing the activity of certain clotting factors that are naturally found in blood. These medications are frequently used to stop blood clot (thrombi) formations in veins or arteries.

Many new developments are also impacting the growth of global antithrombin market. For instance, Antithrombin Kits are developed by Chromogenix Sweden AB. The kit is developed to determine antithrombin activity in human plasma. Apart from traditional thrombin tests, the kit distinguishes between persons who are antithrombin deficient and those who are not. The kit has been modified to work with a variety of automated analyzers, resulting in equivalent response conditions for each analyzer.

However, high pricing of antithrombin drugs may be a restraining factor to the global antithrombin market. For instance, Thrombate III is a human derived antithrombin often utilized in patients on extracorporeal life support with suspected AT-III mediated heparin resistance. It is sold in vials of 500 and 1000 units for $4.66 per unit.

North America, Europe, Asia Pacific, and the rest of the world make up the four geographic divisions that make up the worldwide antithrombin market. The largest share of the global antithrombin market is held by North America. Increased cardiovascular disease cases is the main contributor to the market size of North America market. Strong blood coagulation inhibitors like antithrombins are crucial for treating illnesses connected to the myocardium. The European market is characterized by rapid technological advancement, high level of awareness, and greater drug developments. The Asia Pacific is also anticipated to show lucrative growth throughout the projected period. This is mainly due to the rise in prevalence of coagulation-related illnesses and growing rate of open-heart surgeries in the region.

Some of the prominent market players operating in the global antithrombin market are Gilead Sciences Inc., Strategic Developments, Bristol-Myers Squibb Company, Novartis International AG, Merck & Co., Shire Plc., Kedrion S.p.A, Scripps Laboratories Inc., Lee Biosolutions Plc., Grifols S.A., and CSL Behring GmbH among others

This report entails a thorough quantitative analysis of the trends from 2022 to 2030 in the Antithrombin market The global antithrombin market has been analyzed from four perspectives: Application, Source, Dosage and Region. The applications segment is divided into therapeutics, research, and diagnostics. The source segment is further classified into human, goat milk, and bovine, whereas market size for lyophilized, and liquid dosage forms are also offered in this report.

awards awards key differentiators

Reach Us

enquire@growthplusreports.com

Web –  www.growthplusreports.com